Self-reported cannabis use is inconsistent with the results from drug-screening in youth at ultra high-risk for psychosis in Colorado

Schizophrenia Research

Volumn 157, Issue 1-3, 2014, Pages 317-318

  Carol, Emily E ^a   Mittal, Vijay A ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TETRAHYDROCANNABINOL;

ADOLESCENT; ADULT; CANNABIS ADDICTION; CANNABIS USE; CLINICAL ARTICLE; DRUG ABUSE; DRUG SCREENING; FEMALE; HIGH RISK BEHAVIOR; HIGH RISK PATIENT; HUMAN; LABORATORY TEST; LETTER; MALE; PREDICTION; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; PSYCHOSIS; RISK ASSESSMENT; SELF REPORT; SOCIAL ASPECT; UNITED STATES; URINALYSIS; URINE LEVEL; CANNABIS SMOKING; MARIJUANA ABUSE; RISK; SUBSTANCE ABUSE; URINE;

ADOLESCENT; COLORADO; FEMALE; HUMANS; MALE; MARIJUANA ABUSE; MARIJUANA SMOKING; PSYCHOTIC DISORDERS; RISK; SELF REPORT; SUBSTANCE ABUSE DETECTION;

EID: 84904108633     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2014.05.032     Document Type: Letter

References (9)

1. Addington J., Case N., Saleem M.M., Auther A.M., Cornblatt B.A., Cadenhead K.S. Substance use in clinical high risk for psychosis: a review of the literature. Early Interv. Psychiatry 2013, 10.1111/eip.12100.
2. Auther A.M., McLaughlin D., Carrión R.E., Nagachandran P., Correll C.U., Cornblatt B.A. Prospective study of cannabis use in adolescents at clinical high risk for psychosis: impact on conversion to psychosis and functional outcome. Psychol. Med. 2012, 42(12):2485-2497.
3. Brunette M.F., Drake R.E., Xie H., McHugo G.J., Green A.I. Clozapine use and relapses of substance use disorder among patients with co-occurring schizophrenia and substance use disorders. Schizophr. Bull. 2006, 32(4):637-643.
4. Buchan B.J., Dennis M.L., Tims F.M., Diamond G.S. Cannabis use: consistency and validity of self-report, on-site urine testing and laboratory testing. Addiction 2002, 97(s1):98-108.
5. Drake R., Mueser K.T., McHuge G.J. Clinical Rating Scales: Alcohol Use Scale (AUS), Drug Use Scale (DUS), and Substance Abuse Treatment Scale (SATS). Outcomes Assessment in Clinical Practice 1996, 113-116. Williams and Wilkins, Baltimore. B. Dickey, L.I. Sederer (Eds.).
6. McRae-Clark A.L., Baker N.L., Moran-Santa Maria M., Brady K.T. Effect of oxytocin on craving and stress response in marijuana-dependent individuals: a pilot study. Psychopharmacology 2013, 228(4):623-631.
7. Mizrahi R., Kenk M., Suridjan I., Boileau I., George T.P., McKenzie K., Wilson A.A., Houle S., Rusjan P. Stress-induced dopamine response in subjects at clinical high risk for schizophrenia with and without concurrent cannabis use. Neuropsychopharmacology 2013, 10.1038/npp.2013.347.
8. Woods S.W., Addington J., Cadenhead K.S., Cannon T.D., Cornblatt B.A., Heinssen R., Perkins D.O., Seidman L.J., Tsuang M.T., Walker E.F., McGlashan T.H. Validity of the prodromal risk syndrome for first psychosis: findings from the North American Prodrome Longitudinal Study. Schizophr. Bull. 2009, 35(5):894-908.
9. Wüsthoff L.E., Waal H., Ruud T., Røislien J., Gråwe R.W. Identifying co-occurring substance use disorders in community mental health centres. Tailored approaches are needed. Nord. J. Psychiatry 2011, 65(1):58-64.